ALK and neoplasm: More recently, the identification of molecular lesions in NSCLC, such as activating mutations of the epidermal growth factor receptor (EGFR) gene and fusions of the anaplastic lymphoma kinase (ALK) gene, has yielded targets for small-molecule kinase inhibitors, which often produce regressions and durable tumour control[2].